ReviewAnnals of translational medicine2018
Financial toxicity and implications for cancer care in the era of molecular and immune therapies.
Review in Annals of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Insurance, legal, and financial hardships of childhood and adolescent cancer survivors-a systematic review.Journal of cancer survivorship : research and practice · 2026Pooled it
- Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review.Journal of the National Cancer Institute · 2024Pooled it
- Experiencing financial toxicity associated with cancer in publicly funded healthcare systems: a systematic review of qualitative studies.Journal of cancer survivorship : research and practice · 2022Pooled it
- Financial toxicity associated with a cancer diagnosis in publicly funded healthcare countries: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Pooled it
- A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).International journal of clinical oncology · 2019Trial
- Economic evaluation of added neoadjuvant cemiplimab to upfront wide local excision for advanced cutaneous squamous cell carcinoma of the head and neck.JID innovations : skin science from molecules to population health · 2026Article
- Estimating the Real Option Value of Osimertinib Compared to Standard EGFR-TKI in the Treatment of Advanced NSCLC in the United States.Clinical drug investigation · 2026Article
- Women's experiences toward cervical cancer care at the initiation of care: a qualitative study closing the gap policy and implementation in Indonesia.BMC women's health · 2026Article
- Decoding immunotherapy response through computational modeling.Nature communications · 2026Review
- Biomarker, treatment patterns, and survival differences in metastatic triple-negative breast cancer by race in the United States.NPJ breast cancer · 2026Article
- Total treatment interval and quality of life of women living with breast cancer in Ethiopia: the mediating role of financial toxicity.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Anticancer Bioactive Peptides from Plants: Sources, Action Mechanisms, and Potential Superiority to Conventional Chemotherapy.Probiotics and antimicrobial proteins · 2026Review
- Association between time to treatment and financial toxicity among women with breast cancer in Ethiopia: a multicentre study in a low-resource setting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling.Journal of the National Comprehensive Cancer Network : JNCCN · 2026Article
- Economic Insecurities and Patient-Reported Outcomes Among Cancer Survivors after Receiving External Beam Radiotherapy for Prostate Cancer: A Cross-sectional Study.Urologic nursing · 2026Article
- Assessment of Out-of-Pocket Expenditure of HER2-Positive Breast Cancer Patients in a Tertiary Cancer Center and Private Clinics in the Philippines.Acta medica Philippina · 2026Article
- Mediating Role of Family Resilience and Avoidance Between Financial Toxicity and Quality of Life in Cancer Patients: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Application of digital health interventions in the management of economic toxicity in cancer patients: a scoping review.Frontiers in public health · 2026Article
- Characterizing and Addressing the Financial, Time, and Administrative Burdens of Cancer and its Care.Current treatment options in oncology · 2025Review
- Current Status of Theranostics in West Asia: A Country-based Surveillance Study.Nuclear medicine and molecular imaging · 2025Review
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular and immune therapies have revolutionized cancer treatment and improved patient outcomes and survival. However, the pricing of these drugs has become an issue as the cost of cancer care continues to rise significantly. Cost sharing policies have increased out-of-pocket expenses for patients, leading to poorer financial well-being, quality of life, psychosocial health, and treatment adherence. In this review, we briefly examine some factors affecting the pricing of these new targeted therapies; the effects of financial toxicity on patients; and highlight potential health policy and patient-provider level interventions to address these issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.